2012 Preliminary Program Sessions

  • Recommend
  • Tweet
  • Print
  • Email

1. Globalization of Chinese Companies
This panel will explore the globalization of Chinese companies, starting with the nuances of conducting business with Western biopharma companies and how to go about selling products outside of China. How can Chinese companies find local partners in new territories? What kinds of deal models are most prevalent in the West? Case studies showcasing strong, successful collaborations will provide strategic insight for Chinese companies eager to sell products beyond China’s borders.

2. Achieving Success via Innovation in Biosimilars
Leading companies that have achieved global success in generic drug development, biosimilars and manufacturing will lend their insights on an intriguing panel discussion. What lessons can Chinese companies learn from their stories? How can Chinese companies use business and clinical strategies to position themselves for global success in this growing market?

3. Comparative Legal Systems—U.S., Europe & China
Learn how to navigate the complexities of the European and U.S. regulatory landscapes. What are the barriers to entry in these markets and how can companies gain market access? Regulatory and legal experts will explore the similarities & differences between the U.S., Chinese & European regulatory systems.

4. Development Trends - New Models of R&D Structures in China
There has recently been a flurry of drug development deals between multinational companies and Chinese biopharma companies. Which new models of R&D are being pursued? How does the co-development of biosimilars and new, innovative medicines fit into these research paradigms? How do industry-academic partnerships fit into the R&D model? Industry and academic researcher leaders will explore examples of successful drug development collaborations in China.

5. Biopharma Strategy 101: Biopharma's China Business Plan
Large biotech companies have shown a great interest in China, but have a short history in the country and limited ground operations. How should a Western biotech go about establishing a presence in China? Which operational strategies will allow them to get their innovative therapies into the hands of Chinese patients? A panel of biotech industry experts “trying to figure it out” will share their insights.

6. Adapting to China’s Changing Health Care System—Reimbursement, Health Care Reform & Affordability
Affordability is a central focus of China’s healthcare reforms. What changes in healthcare reform and the private payor markets might occur that can assist with affordability and access? Will new medicines become affordable in China, and can new technologies and developments help create less expensive medicines? What does the looming expansion of the Essential Drug List and National Reimbursement Drug List mean for both Chinese and Western companies? Experts and representatives from the Chinese Government will tackle reimbursement, healthcare reform and private insurance issues.

7. Globalizing Traditional Chinese Medicines
China has used Traditional Chinese Medicine (TCM) for centuries and still comprises a substantial portion of the Chinese healthcare industry. With Western pharmas beginning to show an appetite for these treatments, many in-licensing and co-development opportunities exist. How can Western companies incorporate TCM into their portfolios and what regulations govern these products in China and the West? What pharmaceutical and clinical research processes can companies pursue to further TCM and turn out global, innovative products? Biopharma executives from both China and the West will share their TCM strategies and current projects.

8. Trends in Cancer Research and Oncology Treatment Development in China
Cancer is the leading cause of death in China, and novel oncology treatments are critical to preserving the nation’s public health. This panel will discuss trends in Chinese cancer research and survey the novel oncology drug R&D pipeline for China.

9. Regulatory Review Process of New Medicines in China
The rapid development of the Chinese pharmaceutical industry is presenting new opportunities for new medicine commercialization. Positive steps have been made towards drug registration standardization and the necessary levels of administrative investment. How can both Western and Chinese companies take advantage of China’s review process to create mutually beneficial outcomes for patients and industry? How can the SFDA communicate with companies to improve the review process?

10. Leadership Models in Translating Innovative Sciences
How are Chinese clinicians, researchers, hospital healthcare officials, academia and government agencies incorporating translational medicine into the research process and practice? What agencies and institutions are at the forefront of this effort, and which areas of medicine are likely to benefit first? This panel will provide an overview of China’s translational medicine landscape and highlight U.S. and European programs that could serve as strong models for China.

11. Small Companies Thinking Big: China Operational Strategies
Emerging and mid-sized biotech companies are exploring ways to enter China’s lucrative market and maximize their investment in the country. With more limited resources than multinational biopharma companies, how can these smaller companies operate efficiently and give Chinese patients access to their innovative products? Industry experts and biotech executives will tackle the tough questions surrounding operational tactics in China.
 


 Preliminary program is subject to change.